- Home
- CZNC vs ENGN Comparison
CZNC vs ENGN Comparison
Compare CZNC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ENGN
- Stock Information
- Founded
- CZNC 1864
- ENGN 1999
- Country
- CZNC United States
- ENGN Canada
- Employees
- CZNC N/A
- ENGN N/A
- Industry
- CZNC Major Banks
- ENGN
- Sector
- CZNC Finance
- ENGN
- Exchange
- CZNC Nasdaq
- ENGN Nasdaq
- Market Cap
- CZNC 330.3M
- ENGN 297.7M
- IPO Year
- CZNC N/A
- ENGN N/A
- Fundamental
- Price
- CZNC $19.68
- ENGN $4.35
- Analyst Decision
- CZNC
- ENGN Buy
- Analyst Count
- CZNC 0
- ENGN 9
- Target Price
- CZNC N/A
- ENGN $25.22
- AVG Volume (30 Days)
- CZNC 24.2K
- ENGN 28.9K
- Earning Date
- CZNC 05-06-2025
- ENGN 03-10-2025
- Dividend Yield
- CZNC 5.55%
- ENGN N/A
- EPS Growth
- CZNC 7.45
- ENGN N/A
- EPS
- CZNC 1.69
- ENGN N/A
- Revenue
- CZNC $106,129,000.00
- ENGN N/A
- Revenue This Year
- CZNC $9.38
- ENGN N/A
- Revenue Next Year
- CZNC $3.77
- ENGN N/A
- P/E Ratio
- CZNC $11.96
- ENGN N/A
- Revenue Growth
- CZNC 1.43
- ENGN N/A
- 52 Week Low
- CZNC $16.50
- ENGN $4.20
- 52 Week High
- CZNC $22.68
- ENGN $17.54
- Technical
- Relative Strength Index (RSI)
- CZNC 45.16
- ENGN 32.51
- Support Level
- CZNC $20.24
- ENGN $4.22
- Resistance Level
- CZNC $20.71
- ENGN $5.00
- Average True Range (ATR)
- CZNC 0.44
- ENGN 0.47
- MACD
- CZNC 0.01
- ENGN -0.04
- Stochastic Oscillator
- CZNC 42.14
- ENGN 10.46
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.